Becton, Dickinson and Company (NYSE:BDX) to Buyback $10.00 million in Stock

Becton, Dickinson and Company (NYSE:BDX) declared that its board has authorized a stock buyback plan on Tuesday, January 27th, RTT News reports. The company plans to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Jefferies Financial Group boosted their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Trading Down 0.0%

BDX traded down $0.01 during trading on Tuesday, hitting $203.41. 1,884,824 shares of the stock were exchanged, compared to its average volume of 1,491,532. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The firm has a 50 day simple moving average of $197.87 and a 200 day simple moving average of $190.90. The firm has a market cap of $57.95 billion, a price-to-earnings ratio of 34.89, a P/E/G ratio of 2.25 and a beta of 0.23. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. During the same quarter last year, the firm posted $3.81 EPS. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were paid a dividend of $1.05 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 2,605 shares of company stock valued at $524,643. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.